UBS raised the firm’s price target on 89bio (ETNB) to $38 from $25 and keeps a Buy rating on the shares. Akero Therapeutics (AKRO) reported ...

Inc. (NASDAQ:ETNB), with a market capitalization of $1.14 billion, is a clinical-stage biopharmaceutical company focusing on the development of innovative therapies for the treatment of liver and ...

BofA Securities has recently resumed 89bio Inc (ETNB) stock to Buy rating, as announced on April 22, 2024, according to Finviz. Earlier, on January 12, 2024, RBC Capital Mkts had reduced the stock ...

Pegozafermin. It has two Phase 3 trials: one for MASH and the other for SHTG. See why I continue to rate ETNB stock a buy.

San Francsiscan liver specialist 89bio (Nasdaq: ETNB) has secured $250 million through a public stock offering, following a ...

BioAge scrapped the drug at the center of its $198 million initial public offering last year. Elsewhere, Akero and 89bio raised $600 million combined and Allakos laid off staff.

Akero stock soars 106% in a week following initial positive top line 96-week data from a mid-stage MASH study of its lead ...

Inc. (NASDAQ:ETNB – Get Free Report) was the recipient of some unusual options trading on Monday. Traders acquired 2,228 call options on the company. This is an increase of 346% compared to the ...

Inc. (NASDAQ:ETNB – Get Free Report) has received an average recommendation of “Moderate Buy” from the seven analysts that ...

SAN FRANCISCO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on ...

(NASDAQ: ETNB) couldn't quite keep pace with the broader stock market on Tuesday. Investors were hesitant to buy shares of ...